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ARTICLE

OPEN

Parkinsonian motor impairment predicts personality domains
related to genetic risk and treatment outcomes in schizophrenia
Juan L Molina1,8, María Calvó2,3,8, Eduardo Padilla2,3, Mara Balda1, Gabriela González Alemán2, Néstor V Florenzano4,
Gonzalo Guerrero2,3, Danielle Kamis1, Beatriz Molina Rangeon2,3, Mercedes Bourdieu2,3, Sergio A Strejilevich2, Horacio A Conesa2,4,✠,
Javier I Escobar5, Igor Zwir6, C Robert Cloninger6 and Gabriel A de Erausquin1,7
Identifying endophenotypes of schizophrenia is of critical importance and has profound implications on clinical practice. Here we
propose an innovative approach to clarify the mechanims through which temperament and character deviance relates to risk for
schizophrenia and predict long-term treatment outcomes. We recruited 61 antipsychotic naïve subjects with chronic schizophrenia,
99 unaffected relatives, and 68 healthy controls from rural communities in the Central Andes. Diagnosis was ascertained with the
Schedules of Clinical Assessment in Neuropsychiatry; parkinsonian motor impairment was measured with the Uniﬁed Parkinson’s
Disease Rating Scale; mesencephalic parenchyma was evaluated with transcranial ultrasound; and personality traits were assessed
using the Temperament and Character Inventory. Ten-year outcome data was available for ~ 40% of the index cases. Patients with
schizophrenia had higher harm avoidance and self-transcendence (ST), and lower reward dependence (RD), cooperativeness (CO),
and self-directedness (SD). Unaffected relatives had higher ST and lower CO and SD. Parkinsonism reliably predicted RD, CO, and SD
after correcting for age and sex. The average duration of untreated psychosis (DUP) was over 5 years. Further, SD was anticorrelated
with DUP and antipsychotic dosing at follow-up. Baseline DUP was related to antipsychotic dose-years. Further, ‘explosive/
borderline’, ‘methodical/obsessive’, and ‘disorganized/schizotypal’ personality proﬁles were associated with increased risk of
schizophrenia. Parkinsonism predicts core personality features and treatment outcomes in schizophrenia. Our study suggests that
RD, CO, and SD are endophenotypes of the disease that may, in part, be mediated by dopaminergic function. Further, SD is an
important determinant of treatment course and outcome.
npj Schizophrenia (2017) 2, Article number: 16036; doi:10.1038/npjschz.2016.36; published online 11 January 2017

INTRODUCTION
Schizophrenia is a heritable disorder that causes great psychosocial and interpersonal impairment. Advances in the care and
treatment of severe mental illness in indigenous Latin American
populations are lacking.1 In the case of the indigenous communities in the Central Andes, the problem is further compounded by
limited road availability and mountainous terrain, leading to little
exposure to western medical practices. Kechwa language is the
most prevalent in the region, with more than 10 million speakers,
and includes terms to describe severe depression (llaqui onqoy),
mania (taqui onqoy), and non-affective psychosis not caused by
herbs or alcohol (utiqay); the latter approximating schizophrenia.2
Such terminology correlates with the ability of traditional local
healers to diagnose cases of mental illness.3 Taking advantage of
this unique combination of a population largely unexposed to
medications but able to relate to the concept of psychosis, we
assessed the role of parkinsonism in chronic untreated schizophrenia, and its relationship to behavioral, cognitive and imaging
endophenotypes of risk in unaffected ﬁrst-degree relatives.4–7

Kraepelin described prominent motor abnormalities (lack of
facial expression, rigidity, slowness, and paucity of movement)
along with the better-known psychiatric phenomenology.8 The
introduction of neuroleptics shifted all emphasis on the presence
of such abnormalities to medication side effects, all but ignoring
their contribution to the disease process. The discovery of
neuromotor abnormalities in pre-schizophrenic children renewed
the issue,9,10 leading to conﬁrmations of parkinsonian motor
abnormalities in ﬁrst-episode psychosis11–14 and in treatment
naive chronic schizophrenia.5,15–19 Yet, to the best of our
knowledge the relationship of parkinsonian motor impairment
as mediators of personality traits and clinical outcomes in
antipsychotic naïve patients with schizophrenia and in their
unaffected relatives has not been explored.
Indeed, in Parkinson's disease, a relationship has been clearly
established between deviant personality traits and basal ganglia
dysfunction,20,21 and we recently showed that parkinsonian motor
impairment and substantia nigra hyperechogenicity, a biomarker of
Parkinson disease, are present in neuroleptic naive subjects with
chronic schizophrenia and in their unaffected ﬁrst-degree relatives.5
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Table 1.

Summary of demographic, clinical, and personality variables
Schizophrenia

Relatives

Controls

F

P

Mean

s.e.m.

Mean

s.e.m.

Mean

s.e.m.

28.0
37M/24F
10.0

1.4
—
0.3

40.4
36M/64F
9.9

1.5
—
0.4

30.4
35M/33F
11.1

1.1
—
0.4

22.4
10.0
2.9

o0.001
0.007
0.058

TCI domains—temperament
Novelty seeking
Harm avoidance
Reward dependence
Persistence

96.0
112..8
86.6
103.8

1.8
2.5
1.9
2.7

93.3
105.7
100.4
114.7

1.4
1.5
1.6
2.0

95.4
102.0
103.3
113.1

0.9
1.7
1.9
2.4

1.2
3.5
11.2
2.1

0.309
0.010
o0.001
0.089

TCI domains—character
Self-directedness
Cooperativeness
Self-transcendence
UPDRS-3
Substantia nigra echogenicity left (cm2)
Substantia nigra echogenicity right (cm2)

115.0
119.2
80.8
16.2
0.21
0.25

2.7
2.3
2.4
1.0
0.03
0.03

139.7
131.1
76.9
6.9
0.19
0.16

2.2
1.6
1.8
0.6
0.02
0.02

151.8
137. 4
68.6
4.6
0.2
0.14

2.5
2.0
2.0
0.6
0.03
0.03

20.0
8.8
3.4
31.1
1.9
7.3

o0.001
o0.001
0.011
o0.001
0.111
o0.001

Age
Sex
Education

Abbreviation: TCI, Temperament and Character Inventory.

to longer duration of untreated psychosis and poorer clinical
outcomes.
Personality structures are temporally stable across cultural
contexts,22 and discrete conﬁgurations of personality are heritable
and reﬂect risk for schizophrenia.4,23,24 Thus, the psychobiological
model of personality provides a heuristic explanation for the
relationship of traits associated with risk of disease, pathophysiology, and clinical outcome25–27 including the role of cortical and
subcortical structures on individual differences in personality
traits.28–31
Personality proﬁles of subjects with schizophrenia and their
unaffected relatives have been studied using the Temperament
and Character Inventory (TCI) in a variety of cultural environments
and languages around the world, ﬁnding a disease-state related
pattern consisting of higher harm avoidance and ST with lower
reward dependence (RD), persistence, cooperativeness, and selfdirectedness (SD).4,23,32–35 These personality traits have been
related to symptom proﬁle36,37 and psychosocial function27,38,39 in
patients with chronic schizophrenia. In unaffected relatives,
deviance in character dimensions is consistent with schizotypal
traits,4,23,40 but with some variation across samples.24,32,41
We sought to further elucidate the role of personality structures
in the risk architecture of schizophrenia by including unaffected
relatives and healthy controls (matched to the index subjects) in
our sample. Speciﬁcaly, we proposed to test if an endophenotype
associated with parkinsonism and midbrain hyperechogenicity
predicts deviance on personality traits. We proposed to test the
role of personality deviance as a mediator between parkinsonism
and poor clinical outcomes over the long-term course of the
illness.
Figure 1. Net charts showing Z-scores (0 = mean for healthy
controls, 1 = SD of the mean) for TCI domains (a) and parkinsonism
and dopamine-modulated traits (b). Deviance on individual variables for patients with schizophrenia (yellow triangle) and unaffected relatives (red diamonds) were normalized relative to controls
(blue squares).

Therefore, we hypothesized that parkinsonian motor impairment and hyperechogenicity of the substantia nigra would
predict personality traits also known to correlate with
decreased dopaminergic function, the latter acting as mediators
npj Schizophrenia (2017) 16036

RESULTS
Description of the sample
We studied 61 subjects with schizophrenia, 99 unaffected relatives
(59 siblings and 40 parents), and 68 healthy controls (Table 1).
Average age (mean ± s.d.) was 28 ± 11 for affected subjects,
40 ± 15 for unaffected relatives, and 34 ± 14 for healthy controls.
There were signiﬁcantly more males (60%) among the index
subjects, and more females (64%) among the unaffected relatives.
Years of education were, on average, 10 for subjects with
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Table 2.

Summary of regression analysis
Parkinsonism

Harm avoidance
Reward dependence
Persistence
Self-directedness
Cooperativeness
Self-trancendensce

Right SN echogenicity

Corrected for multiple comparison

β

p

β

P

R2

F

P

0.21
− 0.39
− 0.23
− 0.36
− 0.26
0.13

0.007
o0.001
0.003
o0.001
0.001
0.092

0.11
− 0.17
− 0.01
− 0.07
− 0.12
− 0.004

0.194
0.019
0.887
0.346
0.137
0.966

0.063
0.265
0.057
0.183
0.108
0.025

2.9
15.3
2.6
9.5
5.2
1.1

0.025
o0.001
0.039
o0.001
0.001
0.368

Linear regressions were used to assess the role of parkinsonism and it’s biomarker, the area of SN echogenicity on personality domains that demonstrated
group-level differences. Age and sex were used as covariates.

Figure 2. Parkinsonism predicts core personality traits in schizophrenia and the relationship of self-directedness to course of illness and
outcomes. (a–c) Linear regression between UPDRS3 scores and reward dependence (a, R2 = 0.265, P o0.001), cooperativeness (b, R2 = 0.108,
P = 0.001), and self-directedness (c, R2 = 0.183, Po0.001). 95% Intervals of conﬁdence are also shown. R2-values and signiﬁcance are reported
after correcting for age, sex, and multiple comparisons. In all three cases, severity of motor impairment predicts lower expression of the trait.
Unaffected relatives (green dots) consistently appear between patients (red dots) and healthy controls (blue dots). Panels (d,e). display
regression lines using self-directedness as predictors of duration of untreated psychosis (e, R2 = − 0.075, P = 0.046) and average neuroleptic
dose in chlorpromazine equivalents (d, R2 = − 0.251, P = 0.013). (f) The predicted relationship between duration of untreated psychosis and
cumulative neuroleptic dose (f, R2 = 0.193, P = 0.032).

schizophrenia, 10 for relatives, and 11 for healthy controls. None of
the affected subjects was married, and all were unemployed.
Mean DUP was 45 years.
Temperament and Character Inventory scores for individual scales
differ between risk groups
Temperament scales. Subjects with schizophrenia had higher harm
avoidance (HA) (F = 3.5, P = 0.01) than both unaffected relatives
and controls. Subjects also had lower reward dependence (RD)
(F = 11.2, P o0.001) than both unaffected relatives and controls.
Character scales. Affected subjects and unaffected relatives had
signiﬁcantly higher ST (F = 3.4 P = 0.011) than controls, however,
there were no differences between patients and unaffected

relatives. Both CO (F = 8.8, P o0.001) and SD (F = 20.0, P o 0.001)
follow a graded distribution where subjects scored lowest,
unaffected relatives were intermediate (but signiﬁcantly different
than patients and controls), with controls scoring the highest. See
Figure 1a and Table 1 for summary proﬁles of TCI domains.
Parkinsonism and substantia nigra echogenicity differ between
risk groups
UPDRS3 scores followed a graded distribution with subjects with
schizophrenia being worst, and their unaffected relatives
signiﬁcantly worse than healthy controls (See Table 1; F = 41.7,
P o0.001). On the other hand, echogenicity of the right (but not
left) substantia nigra was signiﬁcantly increased in the affected
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Table 3.

χ2 distributions of personality proﬁles by risk status

Temperament
Explosive 'NHr' (21) versus reliable 'nhR' (26)
Adventurous 'Nhr' (23) versus cautious 'nHR' (15)
Independent 'nhr' (18) versus sensitive 'NHR' (18)
Methodical 'nHr' (27) versus passionate 'nHR' (27)

86.7
64.3
87.5
75

13.3
36.7
12.5
25

43.3
32.5
44.4
46.4

vs.
vs.
vs.
vs.

56.7
67.5
55.6
53.6

26.7
60
36.4
28.6

vs.
vs.
vs.
vs.

73.3
40
63.6
71.4

12.946
3.078
6.859
10.393

0.002
0.218
0.032
0.006

Character
Organized 'SCt' (42) versus schizotypal 'scT' (39)
Apathetic 'sct' (19) versus creative 'SCT' (24)
Bossy 'Sct' (19) versus moody 'sCT' (17)
Dependent 'sCt' (9) versus fanatical 'ScT' (6)

9.4 vs. 90.6
92.9 vs. 7.1
25 vs. 75
100 vs. 0

47.2
33.3
53.8
37.5

vs.
vs.
vs.
vs.

52.8
66.7
46.2
62.5

83.8
25
76.9
66.7

vs.
vs.
vs.
vs.

16.2
75
23.1
33.3

42.968
18.455
7.093
4.812

o0.001
o0.001
0.029
0.090

Resiliency
Fragile 'Hps' (31) versus resilient 'hPS' (36)
Happy-go-Lucky 'hPs' (16) versus high-strung 'HpS'(12)
Conscientious 'HPS' (15) versus laid-back 'hps' (15)
Perfectionist 'HPs' (23) versus self-reliant 'hpS' (27)

95.8 vs. 4.2
80 vs. 20
7.7 vs. 92.3
78.6 vs. 21.4

42.4
55.6
78.6
51.4

vs.
vs.
vs.
vs.

57.6
44.4
21.4
48.6

20.7
21.4
75
29.4

vs.
vs.
vs.
vs.

79.3
78.6
25
70.6

36.351
8.937
17.895
7.798

o0.001
0.011
o0.001
0.020

subjects compared with both unaffected relatives and controls,
(Table 1; F = 7.3, P o0.001), as would be expected for a marker of
genetic risk.
Parkinsonism and SN echogenicity are linear predictors of scores
for individual TCI scales
Figure 1b summarizes the differences in parameters associated
with dopaminergic brain function, between subjects with chronic
untreated schizophrenia, their unaffected ﬁrst-degree relatives
and healthy controls on a z-space (mean = 0, SD = 1). Linear
regressions for individual TCI scales using UPDRS and SN
echogenicity as predictors and age and sex as covariates in the
model revealed signiﬁcant relationships for HA, RD, PS, CO, and SD
(see Table 2). However, after correcting for multiple comparisons
(P = 0.008) only RD, SD, and CO remained signiﬁcant (see
Figures 2a–c, Table 2).
Discriminant Function Analysis using parkinsonism, midbrain
echogenicity, and personality scores as predictors of
schizophrenia risk
To address the classiﬁcation ability of an intermediate phenotype
reﬂecting dopaminergic deﬁcits, we carried out a canonical
discriminant analysis including those variables that were
signiﬁcantly different between groups, namely the TCI scales,
parkinsonism, and right SN echogenic area. Two discriminant
functions were signiﬁcant and accounted for 98.5% and 1.5% of
the total variance respectively, with canonical correlation coefﬁcients of 0.71 (χ2 = 122, P o 0.001) and 0.12 (χ2 = 2.6, P40.05). The
DF1 structure matrix received the largest variance contributions
from UPDRS3, SD, RD, CO, right SN echogenic area, and HA, while
DF2 received variance contributions from ST and PS
(see Supplementary Table 1). Predictions of group membership
(affected, unaffected relative, healthy control) based on DF scores
were correct for 65.7% of all the cases included, regardless of risk
status, with 80% of affected subjects and 70% of healthy controls
being correctly classiﬁed.
Most classiﬁcation errors were due to unaffected relatives, most
likely because of their intermediate expression of disease-related
phenotypes. Therefore, we analyzed the distribution of variables in
unaffected relatives grouped by predicted category membership
assignment (i.e., misclassiﬁed as ‘schizophrenia’ against all other
unaffected relatives) in order to assess the contribution of speciﬁc
variables to assignment errors, which could serve as a proxy
markers of genetic risk. A multivariate analysis of variance
npj Schizophrenia (2017) 16036

Healthy

P

Schizophrenia
vs.
vs.
vs.
vs.

Unaffected

χ2

Contrast (n)

(MANOVA) revealed a signiﬁcant group effect (for predicted
membership) (F = 6.6, observed power = 1.0, Po 0.001); unaffected
relatives misclassiﬁed as subjects with schizophrenia had signiﬁcantly greater parkinsonism (F = 14.6, P o 0.001), and lower RD
(Figure 2b, F = 6.1, P = 0.016), CO (F = 6.8, P = 0.011), and SD
(F = 30.1, P o0.001). There were no signiﬁcant differences in right
substantia nigra, PS, ST between subgroups of unaffected
relatives.
Speciﬁc TCI scales are predictive of DUP in unmedicated chronic
schizophrenia
To assess the relationship between personality domains and
predictors of severity of illness and disability, we derived
exploratory bivariate correlations between TCI domains and
DUP. We found a signiﬁcant negative correlation between SD
and DUP (Figure 2e. R2 = 0.075, P = 0.046, two-tailed). No other
factors reached statistical signiﬁcance.
Speciﬁc TCI scales and DUP are predictive of medication use at
long-term follow-up
In a subgroup analysis where clinical follow-up data were available
(n = 24), we sought to explore relationships between TCI domains
and antipsychotic treatment outcomes. Mean follow-up period
was 9.5 ± 1.8 years. SD was signiﬁcantly anticorrelated with CPZ
equivalents (Figure 2d, R2 = − 0.251, P = 0.013, two-tailed). As
expected, DUP was also associated with dose-years (Figure 2e,
R2 = 0.193, P = 0.032, two-tailed).
Multidimensional personality proﬁles are associated with risk of
schizophrenia
We estimated the associated risk of discrete multidimensional
personality proﬁles by assessing differences in frequencies
between risk groups according to the personality “cubes” schema.
A summary of the distribution of risk groups (affected, unaffected
relative or healthy control) within each personality proﬁle is
displayed in Table 3. The following paragraphs describe the
impact of personality proﬁles on severity of parkinsonism and
midbrain lesion size.
Temperament proﬁles. NHr (explosive/borderline) versus nhR
(reliable). The ‘explosive’ personality type was signiﬁcantly more
frequent in subjects with schizophrenia than in relatives or
controls, and signiﬁcantly more frequent in relatives than in
controls (χ2 = 12.946, P = 0.002).
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Figure 3. Hypothesis testing. Block arrows indicate the direction of
prediction and the statistical method used to tested in each case.

Nhr (adventurous) versus nHR (cautious). No difference was
seen in the distribution of these proﬁles between risk groups.
NHR (sensitive) versus nhr (independent’). The ‘independent’
personality proﬁle was signiﬁcantly more frequent in subjects with
schizophrenia than in relatives or controls, and more frequent in
relatives than in controls (χ2 = 6.86, P = 0.032).
nHr (methodical) versus NhR (passionate). The 'methodical'
(nHr) proﬁle was over-represented in schizophrenia (75%),
whereas the ‘passionate’ proﬁle was over-represented in healthy
controls (72%), and unaffected relatives showed a similar
frequency of both (χ2 = 10.40, P = 0.006).
Character proﬁles. scT (schizotypal/disorganized’) versus Sct
(organized’). The ‘schizotypal/disorganized’ (scT) type was overrepresented in schizophrenia (91%), whereas the ‘organized’ (SCt)
proﬁle was over-represented in healthy controls (84%), and
unaffected relatives had similar frequency of both (χ2 = 42.97,
P o0.001).
sct (apathetic) versus SCT (creative). The ‘apathetic’ (sct)
personality proﬁle was signiﬁcantly more frequent in subjects
with schizophrenia, whereas the ‘creative’ proﬁle was equally
frequent in healthy controls and in unaffected relatives (χ2 = 18.46,
P o0.001).
sCT (moody) versus Sct (bossy). There was a disproportion of the
‘moody’ proﬁle (75%) in subjects with schizophrenia and the
‘bossy’ proﬁle (77%) in healthy controls, while both proﬁles were
equally frequent in unaffected relatives (χ2 = 7.09, P = 0.029).
ScT (fanatical’) versus sCt (dependent’). No differences were
seen for the personality subtypes between risk groups.
Resiliency proﬁles. hPS (resilient) versus Hps (fragile). The ‘fragile’
(Hps) proﬁle was over-represented in schizophrenia (96%), and the
‘resilient’ (hPS) proﬁle was over-represented in healthy controls
(79%), while unaffected relatives were more frequently ‘fragile’
(58%) (χ2 = 36.35, P o0.001).
HpS (high-strung) versus hPs (happy-go-lucky). There was a
disproportion of hPs personality proﬁles (80%) in the schizophrenia group, whereas 79% of healthy controls showed the
complementary HpS personality proﬁle (χ2 = 8.94, P = 0.011).
Similar proportions of each proﬁle were found in unaffected
relatives.
hps (laid-back) versus HPS (conscientious). The hps proﬁle was
over-represented in schizophrenia (92%), whereas each proﬁle
was equally likely in both unaffected relatives and healthy controls
(χ2 = 17.90, P o 0.001).
HPs (perfectionist) versus hpS (self-reliant). We observed a
greater proportion of ‘perfectionist’ (HPs) proﬁle (91%) in subjects
with schizophrenia, whereas 71% of healthy controls were ‘selfreliant’ (hpS) (χ2 = 7.80, P = 0.020). These two proﬁles were equally
likely to be found in unaffected relatives.

DISCUSSION
The TCI has been extensively validated in subjects with schizophrenia and their unaffected relatives.4,25,27,32–37 More speciﬁcally,
we previously showed that in the same population reported here
subjects with untreated psychosis are able to complete the
inventory, albeit on occasion they may require support to stay on
task (they tend to drift off quite easily because of distracting
internal processes). It is most worth pointing out, howerver, that
subjects with untreated psychosis and their unaffected relatives
deviate from healthy controls in predictable fashion, consistent
across samples, indicating that the results are not artifactual or
random. We evaluated a sample of subjects with chronic
untreated schizophrenia at the time of initial assessment, as well
as their unaffected ﬁrst-degree relatives, and healthy matched
controls. High HA, low RD, low SD, low CO and high ST was
associated with greater risk of schizophrenia. Severity of
parkinsonian motor impairment acted as a linear predictor of
RD, CO, and SD after correcting for age and sex (Table 2 and
Figures 2a–c). Unaffected relatives had higher ST and lower CO
and SD than healthy controls, but lower than patients. These
differences were documented in tests of individual traits,
conﬁrming prior work on risk of families of people medicated for
schizophrenia.23,24
We extended prior ﬁndings by showing that speciﬁc multidimensional personality proﬁles, in which disorganization of
emotion, abstract cognition, and motivation is prominent, are
predicted by severity of dopaminergic dysfunction (measured by
parkinsonian motor impairment), and found more frequently in
subjects with chronic untreated schizophrenia and in their
unaffected relatives than in healthy controls, consistent with an
endophenotype (Table 3). Not surprisingly, some of the personality proﬁles associated with parkinsonism are also more frequent
in subjects with schizophrenia than in their unaffected relatives,
indicating a state-dependent marker (Table 3).
Lastly, we found that SD predicted DUP and antipsychotic doses
at follow-up (Figures 2d and e). SD was related to DUP and
antipsychotic dose-years, such that lower SD predicted longer
DUP and higher antipsychotic dosages at follow-up (Figures 2f
and Figure 3).
In the next paragraphs we will consider individual traits ﬁrst,
because prior data is limited to such observations. Then we will
discuss the associations of multidimensional personality proﬁles
with speciﬁc disorganized and negative features underlying risk
some forms of the schizophrenias.
Lastly, we will discuss the role of dopamine deﬁcits expressed
by parkinsonian motor impairment and hyperechogenicity of the
substantia nigra as a pathogenic mechanism mediating the relation
of personality proﬁles to clinical outcomes in schizophrenia.
Parkinsonism and individual personality traits in schizophrenia
Our ﬁndings (high HA, ST and low RD, CO, SD) approximate those
of the only available meta-analysis.35 Prior studies, however,
included subjects either chronically treated or during the ﬁrst
episode of illness. Our study is the ﬁrst to report on subjects with
chronic untreated symptoms at the time of assessment, likely
reﬂecting personality traits intrinsic to the disease process. In
unaffected relatives, we found high ST with low CO and SD, similar
to what is seen in schizotypal personality disorder.40 Since patients
and unaffected relatives share similar genetic contributions and, at
least in part, similar environmental challenges, our design cannot
distinguish the inﬂuence of common environmental factors on
temperament and character from that of genetic liability factors.
HA has been proposed as a core etiopathologic feature of
schizophrenia.24,37,42 We found that severity of parkinsonism acted
as a linear predictor of HA, but on average the trait did not differ
between unaffected relatives and healthy controls. We also found
that RD, CO and SD are predicted by biological markers of
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dopaminergic function (parkinsonism for all three, and midbrain
hyperechogenicity for RD), suggesting that they are related to the
underlying pathophysiology. For CO and SD, unaffected relatives
express an intermediate phenotype between patients and
controls.
Interestingly, RD appears to affect the expression of negative
symptoms.38,41 Neuroimaging studies of RD support a role for
basal ganglia in its expression29–31 and as a putative disease
mechanism.29,43 Conversely, high levels of CO and SD have been
linked to positive outcomes suggesting a possible role in
resilience.23,24,44,45
Not surprisingly, unaffected relatives who were misclassiﬁed as
having schizophrenia in our discriminant analysis, showed lower
RD, CO, SD than those correctly classiﬁed or those misclassiﬁed as
healthy controls. These ﬁndings are similar to studies in ultra highrisk subjects.41
The same misclassiﬁed unaffected relatives also showed greater
parkinsonism than other unaffected relatives. Lower CO and SD
have been thought to reﬂect risk for psychosis.23,24,45 In ultra highrisk samples lower CO has been shown to predict transition to
manifest psychosis.46 Relatives misclassiﬁed as having schizophrenia also had lower RD, possibly representing a tendency for
social withdrawal, as RD measures social attachment and
dependence. In line with this reasoning, studies in prodromal
psychosis have found greater social anhedonia and withdrawal as
predictors of conversion to psychosis,47,48 and others suggested
that RD is associated to genetic vulnerability.41
Even if high-risk individuals never transition to manifest
psychosis, relatives with low CO, SD, and RD may experience
subclinical phenomena that can contribute to signiﬁcant social
dysfunction and a reduced quality of life.41,49 In summary, low RD,
CO, SD, when combined with clinically signiﬁcant parkinsonism,
may represent markers of genetic risk for psychosis.
Lower SD predicted longer DUP in subjects in a sample where
the mean DUP was 45 years. To the best of our knowledge ours is
the ﬁrst report of a personality domain as a linear predictor of DUP
in schizophrenia, as the only previous data comes from subjects
with ﬁrst-episode psychosis50 (and therefore a less stable
diagnoses and shorter DUP).51 This ﬁnding has clinical implications
as a personality domain intrinsic to the disease process is related
to longer DUP, likely leading to worse clinical outcomes.52 Also,
ours is the ﬁrst study relating baseline personality measures
obtained before the initiation of treatment, to prediction of
treatment outcomes. We found that lower SD before the initiation
of treatment predicts greater antipsychotic dosing on follow-up,
which can be viewed as a proxy for treatment refractoriness.
Longer DUP was also related to higher dose-years. Taken together,
a possible interpretation of the data would be that SD contributes
to personality proﬁles such that these individuals suffer from
prolonged social isolation and longer DUP, resulting in more
severe illness course and poorer outcomes.
Parkinsonism and multidimensional personality proﬁles in
schizophrenia
However, when multidimensional personality proﬁles were
considered, we found that in addition to schizotypal personality
(low SD, CO, and high ST), others subjects with chronic
schizophrenia may express explosive (borderline) temperament
(high NS, HA and low RD) and 'methodical (obsessional)'
temperament (low NS, high HA, and low RD). In our prior work
we reported averages for individual traits;4 now we extended our
analyses to individual multidimensional proﬁles and tested their
association with schizophrenia and with parkinsonism. Our
ﬁndings demonstrate that individuals with 'explosive' or 'methodical' temperament proﬁles, 'disorganized' (schizotypal) character
proﬁle, and with plasticity proﬁles described as ambivalent in
npj Schizophrenia (2017) 16036

motivation to act, have more severe parkinsonian motor signs (see
Table 3) and are at greater risk of schizophrenia (see Table 3).
Individuals with ‘explosive’ (high NS, HA, and low RD) and
‘methodical’ (low NS, high HA, and low RD) temperament proﬁles;
‘schizotypal/disorganized’ (low SD, CO and high ST) character
proﬁles; and ‘fragile’ (high HA and low PS, SD) and ‘laid-back’ (low
HA, PS, SD) resiliency proﬁles had greater parkinsonian motor
signs and risk of schizophrenia. Only subjects with the ‘borderline’
temperament proﬁle had signiﬁcantly larger echogenic area of the
right SN on average. It is worth noting that the previous analysis
modeled both personality proﬁles with clinical and imaging
markers of parkinsonism, therefore the associations with increased
risk are in light of clinical parkinsonism.
We further assessed whether these personality proﬁles associated with parkinsonism individually predicted risk of schizophrenia. Interestingly, ‘borderline’ (OR: 4.3, CI: 1.3–14.1, P = 0.01),
‘methodical’ (OR: 4.3, CI: 1.6–11.8, P = 0.003), and ‘schizotypal’ (OR:
9.4, CI: 3.5–24.9, P o0.001) were associated with increased risk of
schizophrenia, whereas the ‘fragile’ and ‘laid-back’ proﬁles were
not associated with schizophrenia in the absence of parkinsonism.
Studies of the premorbid personality of patients with Parkinson
disease without a history of psychosis have previously shown an
association with low NS and high HA.20,53 Low NS is associated
with decreased D2 availability in the insular salience network and
a deﬁcit in the mesolimbic branch of ascending dopamine
transmission in the left hemisphere,54 whereas increased harm
avoidance is associated with greater dopamine loss in the right
striatum53 and increased connectivity of the right anterior insula
with the anterior cingulate and dorsolateral prefrontal cortex.55
Low NS also is strongly related to reduced dopamine synthesis in
the ventral striatum and increased midbrain dopamine autoreceptor availability.56 These individual differences in dopaminergic neurotransmission underlie vulnerability to parkinsonism and
to disturbance of the prefrontal-basal ganglia-prefrotal loop that
may underlie 'disorganized (hebephrenic)' personality types and
negative symptoms, including avolition, blunting of affect, and
ambivalent decision making,57 which is prominent in particular
subtypes of schizophrenia.58 Our ﬁndings speciﬁcally show that
speciﬁc personality proﬁles characterized by 'asociality' (high HA,
low RD), 'ambivalence' (low PS, SD), and 'disorganized thinking'
(low SD, CO, high ST) are associated with more severe
parkinsonian motor symptoms.
These ﬁndings provide a well-documented mechanism for the
relationship of personality to parkinsonism and the pathogenic
role of both on some forms of the schizophrenias. Furthermore,
our ﬁndings suggest the possibility that speciﬁc subsets of the
subjects with chronic untreated schizophrenia ascertained in the
Andes mountains may share pathogenetic mechanisms. For
instance, the speciﬁc disorganized subtype of schizophrenia we
observed in this sample, was assocaited with several genes that
act in concert with an abnormal GOLGA1 gene.58 Indeed, we
previously showed that in the Kechwa sample parkinsonism has a
signiﬁcant association with disorganized and negative symptoms7
and with speciﬁc genome-wide genotypes.59 Further studies of
the phenotypic and genotypic proﬁles of this subgroup are
warranted to test this hypothesis.
Conclusions
Our study is the ﬁrst to relate personality proﬁles to a discrete
well-deﬁned neurological deﬁcit with a known etiopathologic
mechanism, as parkinsonism predicts core features of the
personality structure of at least a subtype of the schizophrenias.
Further, our study extends these observations to unaffected
relatives suggesting that a personality proﬁle can act as an
endophenotype of schizophrenia and is therefore a marker of
genetic risk. Lastly, we found that both parkinsonism and
personality traits at initial assessment are predictive of clinical
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outcomes and course of illness up to ten years later. An important
limitation to our study is the loss of sample size on follow-up, even
though retention rate was quite satisfactory for a study lasting a
decade. Lastly, the fact that our data originate from subjects from
a speciﬁc ethnic group in South America may limit its generalizability. Yet, the fact that the direction and proﬁle of temperament and character deviance in our sample is very similar to that
reported in samples in other countries and cultures—including a
meta-analysis—is very encouraging and supportive of a generalized pathophysiological process, due to the disease and not to the
ethnicity or culture of the sample.
Nonetheless, we believe our data strongly suggest that baseline
personality proﬁles inﬂuence the expression and course of
schizophrenia, therefore warranting further investigation.
MATERIALS AND METHODS
Population and sampling
The recruitment and ascertainment methods of this study were recently
published.6,7 The study was carried out in the Province of Jujuy, Argentina
(population 650 000). Brieﬂy, primary care health agents are in direct
contact with the entire population of the province, and in rural areas visit
every household at least twice a year. When a health agent detects a
possible case of severe mental illness, a notiﬁcation is forwarded to the
investigators using the epidemiological surveillance system of the
province. This system was originally intended for detection/notiﬁcation/
surveillance of transmissible diseases (such as yellow fever, dengue fever,
tuberculosis, etc). We trained health agents to detect, refer and follow-up
cases of severe mental illness.7 Once a case was detected, the mobile
research team contacted them to carry out an evaluation, which was
carried out at the subject's closest health unit. At the outset of the
assessment, participation in research was offered to the subject, his/her
unaffected relatives if available, and to a neighbor matching the subject in
age and sex identiﬁed by the health agent.6,7 If participation in research
was not accepted, the assessment and treatment proceeded through the
Mental Health system of the province, which provides universal care. If
research participation was accepted, all assessments were carried out
blindly by separate members of the team after written informed consent
was completed and included diagnostic ascertainment, neurological, and
neuropsychological examinations.5–7 Diagnostic ascertainment was carried
out using the World Health Organization's Schedules for Clinic Diagnosis in
Neuropsychiatry (SCAN).60 Duration of untreated psychosis (DUP) was also
assessed using SCAN with direct questioning of the subject, collateral
information from family members and any alternate sources of information, such as health or school records. Subjects who met DSM-IV-TR criteria
for schizophrenia and were never exposed to antipsychotic medications
were included in the study. We also recruited at least one sibling or parent
to participate, and a healthy volunteer from the same neighborhood
matched by age, sex, and education to the index subject. Relatives and
healthy controls were also interviewed with SCAN. Additional inclusion
criteria were: (i) age between 18 and 65; and (ii) no neurological or
substance abuse comorbidity. All research procedures, consents, and forms
were independently approved by the Internal Review Board of the Morsani
College of Medicine at University of South Florida, and by the Ethics
Committee of the Ministry of Public Health of the Province of Jujuy,
Argentina.

Temperament and character inventory
The Temperament and Character Inventory (TCI) is a 240 item self-report
assessment of personality dimensions.61 TCI measures temperament (i.e.,
novelty seeking (NS), harm avoidance (HA), RD, persistance (PS)) and
character (i.e., SD, cooperativeness (CO), ST). Temperament refers to
relatively automatic responses to perceptual and emotional stimuli that are
part of the individual's innate behavioral repertoire, whereas character
domains reﬂect learned differences in the attribution of salience and selfconcepts. Speciﬁcally, NS is an expression of an individual’s likeliness to
seek new experiences and novel rewards; HA reﬂects a propensity for
fatigability and the avoidance of punishment; RD resonates a tendency for
social attachment and dependence; PS taps in to an individual’s
conscientious and compulsive qualities; SD measures one’s adaptability
to environmental consequences; CO typiﬁes a sense of agreeableness and
the ability to get along with people; and ST reﬂects the individual’s

integration as a part of the greater universe. To analyze the impact of
multidimensional proﬁles on risk for schizophrenia, we ﬁrst partitioned the
population according each subject's position above (capital letter) or
below (small-caps) the median for each scale (HA -H or h-, NS -N or n-, RD
-R or r-, P -P or p-, SD -S or s-, C -C or c-, and ST -T or t-). We then formed
personality proﬁles according to the three personality “cubes” – temperament, character, and resilience, respectively – by assigning each case
(regardless of diagnostic status) to one of the following dichotomous pairs
(see Table 3). It should be noted that the labels for each proﬁle are
approximate descriptions of its salient features and should not be taken as
comprehensive descriptions.

Motor assessment
A detailed description was published elsewhere.5 Parkinsonism was scored
blindly using Uniﬁed Parkinson's Disease Rating Scale (UPDRS3) on
videotaped exams by independent certiﬁed raters. The scale rates speech,
facial expression, tremor, bradykinesia, akinesia, rigidity, posture and
postural instability, and gait. Since rigidity could not be directly assessed
on the videotapes it was not scored. The minimum clinically signiﬁcant
change in UPDRS-3 scores has been shown to be 46.62

Transcranial ultrasound
Transcranial ultrasound was carried out as previously described.5 Brieﬂy,
we employed a 2.5 MHz transducer (Micromaxx, Sonosite Inc, Bothell, WA,
USA) to examine the brainstem through a pre-auricular acoustic bone
window (penetration depth = 16 cm, dynamic rane = 45 dB) by an expert
sonographist. The substantia nigra was identiﬁed within the butterﬂyshaped structure of the brainstem, scanning from each temporal bone
window. Unbiased quantiﬁcation of the echogenic area was carried out
post hoc on saved images by two different evaluators blind to subject's
condition. Sonographic measurements proved adequately reproducible.

Long-term clinical outcomes
We conducted a follow-up of all affected subjects enrolled in our study.7
For this analysis we included treatment outcome data from individuals
who completed the TCI assessment at ascertainment and had adequate
medical records. Cumulative neuroleptic exposure was computed in doseyears,63 after conversion to chlorpromazine equivalents using published
tables.64,65 A dose-year is deﬁned as the product of the chlorpromazine
equivalents and the time on each dose expressed in years.

Statistical analysis
All variables with signiﬁcant skew deviation or kurtosis were normalized
using log transformations where appropriate. Group differences for
demographic variables were assessed by one-way ANOVA for diagnostic
categories. MANOVA was used to assess the effect of risk status (healthy,
unaffected relative, affected subject) on individual TCI scales with age, sex,
and education as covariates, followed by post hoc Bonferroni (IBM SPSS,
Armonk, NY, USA). Figure 3 describes the sequence of analysis performed
and the hypothesis tested. To assess the inﬂuence of dopaminergic
function on personality domains we derived linear regressions for
individual TCI scales using UPDRS3 and ultrasound as predictors, with
age and sex as covariates. We used a linear discriminant analysis to
determine if TCI scales, UPDRS3, and ultrasound, could predict risk status
(i.e., schizophrenia, unaffected relative, control). A post hoc MANOVA
analysis of unaffected relatives who were misclassiﬁed as ‘schizophrenia’
against all other unaffected relatives in the sample was carried out to
assess for subtle clinical manifestations that could be used to screen for
vulnerability to psychosis. A correlational analysis was conducted between
DUP and TCI domains and between DUP and TCI domains on treatments
outcomes (i.e., chloropromazine equivalents and dose-years). To examine
the relationship of discrete conﬁgurations of personality proﬁles with risk
of schizophrenia, we estimated the proportion of cases, unaffected
relatives and affected subjects for each opposing pair of personality
proﬁles using Chi square distributions, and we calculated the odds ratios
for risk proﬁles associated with schizophrenia. All calculations were
performed on the statistical package SPSS version 22 (IBM Corp, Armonk,
NY, USA).

Published in partnership with the Schizophrenia International Research Society

npj Schizophrenia (2017) 16036

Parkinsonian motor impairment and schizophrenia risk
JL Molina et al

8

ACKNOWLEDGMENTS
This work was funded by NIH grants K08MH077220 and R21TW007882, and in part by
a NARSAD Young Investigator Award to GdE. GdE is Stephen and Constance Lieber and
Sidney R. Baer Jr. Investigator. The authors would like to dedicate this article in
memoriam Prof. Dr Horacio A. Conesa, beloved mentor, teacher, and friend.

COMPETING INTERESTS
The authors declare no conﬂict of interest.

REFERENCES
1. Incayawar, M. & Maldonado-Bouchard, S. The forsaken mental health of the
Indigenous Peoples—a moral case of outrageous exclusion in Latin America. BMC
Int. Health Hum. Rights 9, 27 (2009).
2. Elferink, J. G. Mental disorder among the Incas in ancient Peru. Hist. Psychiatry 10,
303–318 (1999).
3. Incayawar, M. Efﬁcacy of Quichua healers as psychiatric diagnosticians. Br. J.
Psychiatry J. Ment. Sci 192, 390–391 (2008).
4. Calvó de Padilla, M. et al. Temperament traits associated with risk of schizophrenia in an indigenous population of Argentina. Schizophr. Res. 83,
299–302 (2006).
5. Kamis, D. et al. Sex and laterality differences in parkinsonian impairment
and transcranial ultrasound in never-treated schizophrenics and their
ﬁrst degree relatives in an Andean population. Schizophr. Res. 164,
250–255 (2015).
6. Padilla, E. et al. The efﬁcacy of targeted health agents education to reduce the
duration of untreated psychosis in a rural population. Schizophr. Res. 161,
184–187 (2015).
7. Balda, M. et al. Detection, assessment, and management of schizophrenia in an
Andean population of South America: parkinsonism testing and transcranial
ultrasound as preventive tools. FOCUS 13, 432–440 (2015).
8. Kraepelin, E. Dementia Praecox and Paraphrenia. (Thoemmes, 2002).
9. Walker, E. F., Savoie, T. & Davis, D. Neuromotor precursors of schizophrenia.
Schizophr. Bull. 20, 441–451 (1994).
10. Schiffman, J. et al. Childhood videotaped social and neuromotor precursors of
schizophrenia: a prospective investigation. Am. J. Psychiatry 161,
2021–2027 (2004).
11. Cortese, L. et al. Relationship of neuromotor disturbances to psychosis symptoms
in ﬁrst-episode neuroleptic-naive schizophrenia patients. Schizophr. Res. 75,
65–75 (2005).
12. Chakos, M. H., Mayerhoff, D. I., Loebel, A. D., Alvir, J. M. & Lieberman, J. A.
Incidence and correlates of acute extrapyramidal symptoms in ﬁrst episode of
schizophrenia. Psychopharmacol. Bull. 28, 81–86 (1992).
13. Cuesta, M. J. et al. Spontaneous parkinsonism is associated with cognitive
impairment in antipsychotic-naive patients with ﬁrst-episode psychosis: a
6-month follow-up study. Schizophr. Bull. 40, 1164–1173 (2014).
14. Peralta, V. & Cuesta, M. J. Neuromotor abnormalities in neuroleptic-naive psychotic patients: antecedents, clinical correlates, and prediction of treatment
response. Compr. Psychiatry 52, 139–145 (2011).
15. Molina J. L. et al. Prediction of neurocognitive deﬁcits by parkinsonian motor
impairment in schizophrenia: a study in neuroleptic-naïve subjects, unaffected
ﬁrst-degree relatives and healthy controls from an indigenous population.
Schizophr. Bull. 2016; 42: 1486–1495.
16. Honer, W. G., Kopala, L. C. & Rabinowitz, J. Extrapyramidal symptoms and signs in
ﬁrst-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J. Psychopharmacol. Oxf. Engl. 19,
277–285 (2005).
17. McCreadie, R. G., Srinivasan, T. N., Padmavati, R. & Thara, R.
Extrapyramidal symptoms in unmedicated schizophrenia. J. Psychiatr. Res. 39,
261–266 (2005).
18. Fervaha, G. et al. Extrapyramidal symptoms and cognitive test performance in
patients with schizophrenia. Schizophr. Res. 161, 351–356 (2015).
19. Peralta, V. et al. Characterization of the deﬁcit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological
soft signs. Schizophr. Bull. 40, 214–224 (2014).
20. Kaasinen, V. et al. Personality traits and brain dopaminergic function in Parkinson’s disease. Proc. Natl Acad. Sci. USA 98, 13272–13277 (2001).
21. Jerussi, T. P. & Taylor, C. A. Bilateral asymmetry in striatal dopamine
metabolism: implications for pharmacotherapy of schizophrenia. Brain Res. 246,
71–75 (1982).
22. Svrakic, D. M. & Cloninger, R. C. Epigenetic perspective on behavior
development, personality, and personality disorders. Psychiatr. Danub. 22,
153–166 (2010).

npj Schizophrenia (2017) 16036

23. Smith, M. J., Cloninger, C. R., Harms, M. P. & Csernansky, J. G. Temperament and
character as schizophrenia-related endophenotypes in non-psychotic siblings.
Schizophr. Res. 104, 198–205 (2008).
24. Bora, E. & Veznedaroglu, B. Temperament and character dimensions of the
relatives of schizophrenia patients and controls: the relationship between
schizotypal features and personality. Eur. Psychiatry J. Assoc. Eur. Psychiatr. 22,
27–31 (2007).
25. Margetić, B. A., Jakovljević, M., Brataljenović, T. & Sumić, M. Personality and
schizophrenia: psychobiological model and its relationship with comorbidity.
Psychiatr. Danub. 21, 356–360 (2009).
26. Margetić, B. A. & Jakovljević, M. Psychobiological model of personality and
psychopharmacotherapy outcomes in treatment of depression and schizophrenia. Psychiatr. Danub. 25, 324–328 (2013).
27. Margetić, B. A., Jakovljević, M., Ivanec, D. & Margetić, B. Temperament, character,
and quality of life in patients with schizophrenia and their ﬁrst-degree relatives.
Compr. Psychiatry 52, 425–430 (2011).
28. Pujol, J. et al. Anatomical variability of the anterior cingulate gyrus and basic
dimensions of human personality. NeuroImage 15, 847–855 (2002).
29. Buckholtz, J. W. et al. Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality. Mol.
Psychiatry 13, 313–324 (2008).
30. Gardini, S., Cloninger, C. R. & Venneri, A. Individual differences in personality traits
reﬂect structural variance in speciﬁc brain regions. Brain Res. Bull. 79,
265–270 (2009).
31. Van Schuerbeek, P., Baeken, C., De Raedt, R., De Mey, J. & Luypaert, R. Individual
differences in local gray and white matter volumes reﬂect differences in
temperament and character: a voxel-based morphometry study in healthy young
females. Brain Res. 1371, 32–42 (2011).
32. Gonzalez-Torres, M. A. et al. Temperament and character dimensions in
patients with schizophrenia, relatives, and controls. J. Nerv. Ment. Dis. 197,
514–519 (2009).
33. Guillem, F., Pampoulova, T., Rinaldi, M. & Stip, E. Temperament and executive
dysfunctions in schizophrenia. Schizophr. Res. 104, 175–184 (2008).
34. Hori, H. et al. Personality in schizophrenia assessed with the temperament and
character Inventory (TCI). Psychiatry Res. 160, 175–183 (2008).
35. Ohi, K. et al. Personality traits and schizophrenia: evidence from a case-control
study and meta-analysis. Psychiatry Res. 198, 7–11 (2012).
36. Lysaker, P. H., Bell, M. D., Kaplan, E., Greig, T. C. & Bryson, G. J. Personality and
psychopathology in schizophrenia: the association between personality traits and
symptoms. Psychiatry 62, 36–48 (1999).
37. Aukst-Margetić, B., Jakšić, N., Boričević Maršanić, V. & Jakovljević, M. Harm
avoidance moderates the relationship between internalized stigma and
depressive symptoms in patients with schizophrenia. Psychiatry Res. 219,
92–94 (2014).
38. Poustka, L. et al. The inﬂuence of temperament on symptoms and functional
outcome in people with psychosis in the Northern Finland 1966 Birth Cohort. Eur.
Psychiatry J. Assoc. Eur. Psychiatr. 25, 26–32 (2010).
39. Jetha, M. K., Goldberg, J. O. & Schmidt, L. A. Temperament and its relation to
social functioning in schizophrenia. Int. J. Soc. Psychiatry 59, 254–263 (2013).
40. Daneluzzo, E., Stratta, P. & Rossi, A. The contribution of temperament
and character to schizotypy multidimensionality. Compr. Psychiatry 46,
50–55 (2005).
41. Glatt, S. J., Stone, W. S., Faraone, S. V., Seidman, L. J. & Tsuang, M. T.
Psychopathology, personality traits and social development of young ﬁrst-degree
relatives of patients with schizophrenia. Br. J. Psychiatry J. Ment. Sci 189,
337–345 (2006).
42. Sim, M., Kim, J. H., Yim, S. J., Cho, S.-J. & Kim, S. J. Increase in harm avoidance by
genetic loading of schizophrenia. Compr. Psychiatry 53, 372–378 (2012).
43. Hägele, C. et al. Dimensional psychiatry: reward dysfunction and depressive
mood across psychiatric disorders. Psychopharmacology (Berl.) 232,
331–341 (2015).
44. Eklund, M. & Hansson, L. Determinants of satisfaction with community-based
psychiatric services: a cross-sectional study among schizophrenia outpatients.
Nord. J. Psychiatry 55, 413–418 (2001).
45. Eklund, M., Hansson, L. & Bengtsson-Tops, A. The inﬂuence of temperament
and character on functioning and aspects of psychological health among
people with schizophrenia. Eur. Psychiatry J. Assoc. Eur. Psychiatr 19, 34–41
(2004).
46. Song, Y. Y. et al. Temperament and character in individuals at ultra-high risk for
psychosis and with ﬁrst-episode schizophrenia: associations with psychopathology, psychosocial functioning, and aspects of psychological health. Compr.
Psychiatry 54, 1161–1168 (2013).
47. Cannon, T. D. et al. Prediction of psychosis in youth at high clinical risk: a
multisite longitudinal study in North America. Arch. Gen. Psychiatry 65,
28–37 (2008).

Published in partnership with the Schizophrenia International Research Society

Parkinsonian motor impairment and schizophrenia risk
JL Molina et al

9
48. Velthorst, E. et al. Baseline differences in clinical symptomatology between ultra
high risk subjects with and without a transition to psychosis. Schizophr. Res. 109,
60–65 (2009).
49. Fresán, A. et al. Personality features in ultra-high risk for psychosis: a comparative
study with schizophrenia and control subjects using the Temperament and
Character Inventory-revised (TCI-R). J. Psychiatr. Res. 61, 168–173 (2015).
50. Compton, M. T. et al. Personality domains, duration of untreated psychosis,
functioning, and symptom severity in ﬁrst-episode psychosis. Schizophr. Res. 168,
113–119 (2015).
51. Tohen, M. et al. Two-year outcomes in ﬁrst-episode psychotic depression the
McLean-Harvard First-Episode Project. J. Affect. Disord. 136, 1–8 (2012).
52. Marshall, M. et al. Association between duration of untreated psychosis and
outcome in cohorts of ﬁrst-episode patients: a systematic review. Arch. Gen.
Psychiatry 62, 975–983 (2005).
53. Tomer, R. & Aharon-Peretz, J. Novelty seeking and harm avoidance in Parkinson’s
disease: effects of asymmetric dopamine deﬁciency. J. Neurol. Neurosurg.
Psychiatry 75, 972–975 (2004).
54. Kaasinen, V., Aalto, S., Någren, K. & Rinne, J. O. Insular dopamine D2 receptors and
novelty seeking personality in Parkinson’s disease. Mov. Disord. Off. J. Mov. Disord.
Soc 19, 1348–1351 (2004).
55. Markett, S. et al. Intrinsic connectivity networks and personality: the temperament dimension harm avoidance moderates functional connectivity in the
resting brain. Neuroscience 240, 98–105 (2013).
56. Zald D. H. et al. Midbrain dopamine receptor availability is inversely associated
with novelty-seeking traits in humans. J. Neurosci. 2008; 28: 14372–14378.
57. Levy, R. & Dubois, B. Apathy and the functional anatomy of the prefrontal
cortex-basal ganglia circuits. Cereb. Cortex 16, 916–928 (2006).
58. Arnedo, J. et al. Uncovering the hidden risk architecture of the schizophrenias:
conﬁrmation in three independent genome-wide association studies. Am. J.
Psychiatry 172, 139–153 (2014).

59. Arnedo, J. et al. PGMRA: a web server for (phenotype x genotype)
many-to-many relation analysis in GWAS. Nucleic Acids Res. 41,
W142–W149 (2013).
60. Wing, J. K. et al. SCAN. Schedules for clinical assessment in neuropsychiatry. Arch.
Gen. Psychiatry 47, 589–593 (1990).
61. Cloninger, C. R., Svrakic, D. M. & Przybeck, T. R. A psychobiological model of
temperament and character. Arch. Gen. Psychiatry 50, 975–990 (1993).
62. Hauser, R. A. et al. Minimal clinically important difference in parkinson’s disease
as assessed in pivotal trials of pramipexole extended release. Park. Dis. 2014,
1–8 (2014).
63. Andreasen, N. C., Pressler, M., Nopoulos, P., Miller, D. & Ho, B.-C. Antipsychotic
dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 67, 255–262 (2010).
64. Woods, S. W. Chlorpromazine equivalent doses for the newer atypical
antipsychotics. J. Clin. Psychiatry 64, 663–667 (2003).
65. Lehman, A. F. et al. The Schizophrenia Patient Outcomes Research
Team (PORT): updated treatment recommendations 2003. Schizophr. Bull. 30,
193–217 (2004).

This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/

© The Author(s) 2017

Supplementary Information accompanies the paper on the npj Schizophrenia website (http://www.nature.com/npjschz)

Published in partnership with the Schizophrenia International Research Society

npj Schizophrenia (2017) 16036

